🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

BeBetter Med clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with BeBetter Med as lead sponsor. Synced 26 Sep 2026
8Current trials
7Recruiting now
16Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

BeBetter Med is the lead sponsor of 8 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, BEBT-109 and BEBT-209. The most-studied condition is Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

ClinicalTrials.gov trials by status

  • Recruiting788%
  • Not yet open113%

Trials by phase

  • Phase 2338%
  • Phase 3225%
  • Phase 2/3113%
  • Phase 1/2113%
  • Phase 1113%
01

Clinical trials sponsored by BeBetter Med

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06792253 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3 Recruiting 2025-01 China
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT07544056 · ClinicalTrials.gov ↗ · Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Phase 2/3 Recruiting 2026-06 China
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
NCT06998108 · ClinicalTrials.gov ↗ · HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Phase 3 Recruiting 2022-06 China
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
NCT06514027 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Phase 2 Recruiting 2024-08 China
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol(LDL-C)
NCT07368608 · ClinicalTrials.gov ↗ · Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
Phase 1/2 Recruiting 2026-03 China
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
NCT07012109 · ClinicalTrials.gov ↗ · Polycythemia Vera
Phase 1 Recruiting 2025-06 China
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
NCT06706713 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
Drug: BEBT-109
Phase 2 Recruiting 2022-04 China
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
NCT07676175 · ClinicalTrials.gov ↗ · Previously Untreated Peripheral T-Cell Lymphoma
Phase 2 Not yet open 2026-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in BeBetter Med trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in BeBetter Med trials

10 conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma1Locally Advanced Triple-negative Breast Cancer1Metastatic Triple-negative Breast Cancer1Previously Untreated Peripheral T-Cell Lymphoma1HR+/HER2- Locally Advanced, Metastatic Breast Cancer1Non Small Cell Lung Cancer1Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol1Polycythemia Vera1Non-Small Cell Lung Cancer1EGFR Exon 20 Insertion Mutation1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China87

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

SponsorTrials
Hutchmed2

Sponsors with the most current trials registered for this condition.

06

Questions about BeBetter Med trials

How many clinical trials does BeBetter Med sponsor?

BeBetter Med is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are BeBetter Med trials recruiting?

Yes. 7 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is BeBetter Med testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are Carboplatin (3), BEBT-109 (2), BEBT-209 (2), Gemcitabine Hydrochloride (2) and Ifupinostat Hydrochloride (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.